Table 3. Prevalence of lipid abnormalities among patients receiving ART by types of ART regimen.
| ART regimens | TC ≥ 200 mg/dl | TG ≥ 150 mg/dl | HDL-c < 40 mg/dl | LDL-c ≥ 130 mg/dl | TC/HDL-c ratio ≥5 |
|---|---|---|---|---|---|
| n = 185 (%) | n = 121 (%) | n = 76 (%) | n = 116 (%) | n = 54 (%) | |
| NRTI regimens | |||||
| TDF-based | 81 (49.1) | 49 (29.7) | 30 (18.2) | 53 (32.6) | 24 (14.5) |
| AZT-based | 76 (48.7) | 50 (32.1) | 32 (20.5) | 45 (28.8) | 21 (13.5) |
| D4T-based | 28 (39.4) | 22 (31.0) | 14 (19.7) | 18 (25.4) | 9 (12.7) |
| P-value | 0.350 | 0.901 | 0.867 | 0.560 | 0.920 |
| NNRTI regimens | |||||
| NVP-based | 103 (47.9) | 65 (30.2) | 40 (18.6) | 67 (31.2) | 26 (12.1) |
| EFV-based | 82 (48.3) | 56 (31.6) | 36 (20.3) | 49 (27.7) | 28 (15.8) |
| P-value | 0.755 | 0.764 | 0.666 | 0.453 | 0.287 |
ART, antiretroviral therapy; TC, total cholesterol; TG, triglyceride; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol, NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, nonnucleoside reverse transcriptase inhibitors; TDF, tenofovir; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; NVP, nevirapine